Synthes Chooses Alternative-To-BMP Route In Bone Growth Factor Search
This article was originally published in The Gray Sheet
Executive Summary
Synthes-Stratec plans to forego immediate development of an orthobiologic bone growth factor, citing doubts about the product's feasibility in musculoskeletal repair applications